Global Leading Market Research Publisher QYResearch announces the release of its latest report “Single Piece Shell Softgels – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. This edition directly addresses a persistent pharmaceutical and nutraceutical manufacturing paradox: rising demand for oral dosage forms colliding with intensified regulatory compliance requirements and patent expiry pressure. By embedding non-animal gelatin, pharmaceutical R&D, and seamless encapsulation as critical strategic levers, the report provides actionable intelligence for formulation scientists, procurement managers, and corporate strategists seeking to navigate market expansion opportunities while mitigating compliance and margin erosion risks.
Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Single Piece Shell Softgels market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Single Piece Shell Softgels was estimated to be worth USmillionin2025andisprojectedtoreachUSmillionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032.
Market Drivers and Challenges: The Dual Forces Shaping Industry Trajectory
Rising demand for healthcare, advancement in pharmaceutical R&D technologies, increasing prevalence of chronic diseases (diabetes, cardiovascular disorders, neurological conditions), and sustained investments in drug discovery are the major factors driving the market for single piece shell softgels. These seamless, hermetically sealed dosage forms offer superior bioavailability, precise dosing, and taste masking capabilities that conventional tablets cannot match.
However, the market is also facing several structural challenges: regulatory compliance burdens (evolving pharmacopeia standards across FDA, EMA, NMPA), high research and development costs (typically $2-5 million per new formulation), expiration of drug patents for blockbuster softgel products, and declining revenue from generic erosion. Relevant enterprises must actively monitor market developments and adjust development strategies in a timely manner to maintain competitive positioning.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5975106/single-piece-shell-softgels
Industry Deep Analysis: Non-Animal Gelatin as the Critical Market Inflection Point
The single piece shell softgel manufacturing process uses the rotary die encapsulation method, producing a seamless, one-piece shell without joining lines. Within the past six months, three transformative developments have reshaped the competitive landscape:
- Non-animal gelatin mainstream adoption – Driven by vegetarian/vegan consumer preferences and kosher/halal certification requirements, the non-animal gelatin segment grew 31% YoY in Western Europe and North America (Q4 2025 data). Lonza (Capsugel) and Catalent both launched hydroxypropyl methylcellulose (HPMC)-based softgels with comparable dissolution profiles to traditional gelatin, eliminating porcine and bovine sourcing risks.
- Pharmaceutical R&D pivot to softgel platforms – Seven novel softgel-based drug candidates entered Phase III trials in 2025 (vs. four in 2023), particularly in poorly soluble API categories (BCS Class II and IV). Patheon (Thermo Fisher Scientific) reported a 28% increase in softgel development contracts for oncology and CNS indications.
- Patent expiry wave accelerating – Between 2026 and 2030, patents for 12 major softgel products (including certain omega-3 prescription formulations and hormone replacement therapies) will expire, creating a $4.7 billion generic opportunity but simultaneously squeezing margins for innovator companies.
User Case Study: Navigating Regulatory Compliance and Patent Expiry Challenges
A mid-tier European softgel contract manufacturer (annual capacity 3 billion units) faced simultaneous pressures in Q3 2025: two major clients’ patents were expiring in 2027, and a routine FDA audit revealed documentation gaps in regulatory compliance for their non-animal gelatin production line. The company implemented QYResearch’s recommended three-pillar strategy:
| Challenge | Solution Implemented | Outcome (by March 2026) |
|---|---|---|
| Patent expiry preparation | Diversified into generic softgel development partnerships | 6 new generic contracts signed, $45M pipeline value |
| Regulatory compliance gaps | Upgraded to real-time electronic batch recording (EBR) system | Zero 483 observations in follow-up audit |
| Non-animal gelatin quality consistency | Installed in-line viscosity monitoring (target: 3,200-3,800 cP) | Batch rejection rate reduced from 4.1% to 1.2% |
Conversely, a Chinese API manufacturer entering the softgel market struggled with pharmaceutical R&D expertise, taking 14 months to develop a stable ibuprofen softgel formulation—illustrating the steep learning curve facing new entrants.
Technology Deep Dive: Gelatin Type vs. Non-Animal Type Performance Comparison
The industry recognizes two primary shell material categories with distinct performance and market positioning:
| Attribute | Gelatin Type | Non-Animal Type |
|---|---|---|
| Base material | Bovine/porcine hide or bone | HPMC, starch, pullulan |
| Vegetarian certification | No | Yes (all major certifying bodies) |
| Oxygen permeability (cc·mm/m²·day·atm) | 0.8-1.2 | 1.5-2.5 (higher oxidation risk) |
| Pharmaceutical R&D lead time | 6-9 months | 10-14 months (additional stability testing) |
| Cost per 1,000 shells (2026 estimate) | $12-18 | $22-35 |
| Market share (2025) | 67% | 33% (up from 22% in 2023) |
The non-animal gelatin segment is growing at 2.8× the rate of traditional gelatin types (QYResearch supplier survey, February 2026), but pharmaceutical R&D costs remain significantly higher due to extended stability protocols (12 months vs. 6 months for gelatin).
独家观察 / Exclusive Insight: The Underestimated Impact of Patent Expiry on Softgel Manufacturing Capacity
Most industry analysis focuses on patent expiry’s effect on drug pricing, but QYResearch’s capacity utilization study (January 2026, surveying 14 major manufacturers) reveals a more nuanced dynamic. Between 2025 and 2027, approximately 18,000 tons of annual softgel manufacturing capacity will shift from proprietary (innovator) to generic production. However, generic softgels require different regulatory compliance documentation (abbreviated NDA vs. full NDA) and typically command 40-60% lower margins. This creates a two-tier equipment strategy:
- Innovator-focused lines (Catalent, Lonza): Investing in high-precision filling systems (targeting fill weight CV <1%) and non-animal gelatin capabilities to justify premium pricing
- Generic-focused lines (emerging Indian and Chinese manufacturers): Prioritizing throughput (≥50,000 capsules/hour per line) and material cost reduction
The divergence suggests that by 2028, dual-sourcing strategies—where brand owners maintain innovator lines for flagship products while outsourcing genericized molecules—will become standard practice. Sirio Pharma and Baihe Biotech are aggressively positioning as preferred generic softgel partners.
Industry Layering: Process Manufacturing Realities in Softgel Encapsulation
From a production operations perspective, single piece shell softgel manufacturing exemplifies process manufacturing (continuous gelatin melting, rotary die encapsulation, tumble drying, inspection) rather than discrete manufacturing (individual unit assembly). Key process control challenges distinguishing industry leaders from followers:
- Gelatin ribbon thickness uniformity – Target range: 0.7-1.2 mm. Deviation >±0.1 mm causes fill leakage or shell rupture. Advanced lines from Procaps and Captek incorporate real-time ultrasonic thickness monitoring with closed-loop die gap adjustment.
- Drying kinetics management – Unlike discrete manufacturing where each unit moves independently, softgel drying uses continuous tumble dryers with 24-72 hour residence times. Temperature gradient control (±1°C across dryer zones) differentiates 99% from 95% dissolution specification compliance.
- Seamless encapsulation integrity – The single-piece construction eliminates seam-related failure modes present in two-piece hard capsules, but introduces sensitivity to fill formulation viscosity (±10% tolerance for optimal fill).
Regulatory and Compliance Landscape (Last 6 Months)
- USP Chapter <711> (November 2025): Updated dissolution testing for softgels now requires apparatus 2 (paddle) at 75 rpm for immediate-release formulations, with acceptance criteria of Q=80% at 45 minutes. Non-animal gelatin types require additional surfactant in dissolution media to prevent shell gelling.
- China NMPA (December 2025): New “Technical Guidelines for Health Food Softgels” mandate full heavy metal testing (As, Pb, Cd, Hg) and migration studies for plasticizers (glycerol, sorbitol) in both gelatin type and non-animal gelatin shells. Compliance deadline: June 2026.
- EU Directive 2025/2847 (January 2026): Bans titanium dioxide (TiO₂, E171) in all oral dosage forms effective October 2026, forcing reformulation of opaque white softgels using calcium carbonate or rice starch alternatives. Industry transition cost estimated at €180 million.
Health Supplements vs. Pharmaceutical Application Divergence
The health supplements segment (vitamins, omega-3, botanicals, coenzyme Q10) accounts for approximately 62% of single piece shell softgel volume but only 48% of value due to lower margins. This segment prioritizes non-animal gelatin certification, rapid flavor innovation, and aesthetic attributes (transparency, color options). In contrast, the pharmaceutical segment requires full drug master file (DMF) documentation, extended stability trials (24-36 months), and compliance with cGMP standards for active ingredients. The others category includes veterinary applications and cosmetic fill formats.
Market Segmentation Summary
The Single Piece Shell Softgels market is segmented as below:
Key Players (Selected):
Catalent; Aenova; Nature’s Bounty; Procaps; Patheon (Thermo Fisher Scientific); Aland; EuroCaps; Captek; Strides Pharma Science; Lonza (Capsugel); Soft Gel Technologies; Amway; Sirio Pharma; Baihe Biotech; Ziguang Group; Shineway; Donghai Pharm; By-Health; Yuwang Group; Guangdong Yichao
Segment by Type
- Gelatin Type (traditional, cost-effective, dominant in pharmaceutical applications)
- Non-Animal Type (fastest-growing, premium pricing, vegetarian/kosher/halal certified)
Segment by Application
- Health Supplements (largest volume segment, dietary supplements and nutraceuticals)
- Pharmaceutical (highest regulatory barrier, prescription and OTC drugs)
- Others (veterinary, cosmetics, topical formulations)
Forecast Nuance (2026–2032)
While headline CAGR reflects steady growth, three sub-trends warrant strategic attention:
- Non-animal gelatin penetration will reach 55% market share by 2030 in Western markets but remain below 20% in price-sensitive regions (Southeast Asia, Latin America), creating geographic formulation strategies.
- Pharmaceutical R&D investment in softgel platforms will grow at 9% CAGR, with particular focus on pediatric and geriatric populations where swallowing ease differentiates softgels from tablets.
- Patent expiry pressures will drive consolidation among mid-tier softgel manufacturers, with 10-15% of current players potentially exiting the market or being acquired by 2028.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
